| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRANSCI.2009.07.004 |
| P698 | PubMed publication ID | 19717344 |
| P2093 | author name string | Neelam Marwaha | |
| R R Sharma | |||
| P2860 | cites work | Evaluation of platelet transfusion triggers in a tertiary-care hospital | Q28288397 |
| The outbreak of West Nile virus infection in the New York City area in 1999 | Q29618175 | ||
| Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates | Q30431256 | ||
| Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients | Q30466468 | ||
| The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients | Q33328580 | ||
| Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 | ||
| Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions | Q33340587 | ||
| Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation | Q33344146 | ||
| Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial | Q33345486 | ||
| Platelet dosing | Q33347834 | ||
| Guidelines for the use of platelet transfusions | Q33348675 | ||
| Prophylactic platelet transfusions: which dose is the best dose? A review of the literature | Q33349172 | ||
| Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force | Q33351618 | ||
| The quantitative relation between platelet count and hemorrhage in patients with acute leukemia | Q33353564 | ||
| Transfusions of Fresh Platelet Concentrates to Patients with Secondary Thrombocytopenia | Q33354123 | ||
| Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial | Q33360736 | ||
| Optimizing platelet transfusion therapy | Q33361167 | ||
| Estimation and predictive use of the corrected count increment--a proposed clinical guideline | Q33365212 | ||
| Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction | Q33367647 | ||
| A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation | Q33369834 | ||
| Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia | Q33371869 | ||
| Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses | Q33372452 | ||
| Platelet utilization and the transfusion trigger: a prospective analysis | Q33374264 | ||
| Platelet transfusion refractoriness | Q33379775 | ||
| A model to determine required pool size for HLA-typed community donor apheresis programs | Q33432260 | ||
| A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients | Q33449659 | ||
| Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates | Q33457135 | ||
| Flow cytometric detection of platelet-reactive antibodies and application in platelet crossmatching | Q33495488 | ||
| The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. | Q33501152 | ||
| Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion-dependent patient | Q33503153 | ||
| ABH antigens on human platelets: expression on the glycosyl phosphatidylinositol-anchored protein CD109. | Q33503358 | ||
| Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program | Q33726826 | ||
| Optimal dosing and triggers for prophylactic use of platelet transfusions | Q33765277 | ||
| Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light | Q34322353 | ||
| Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective | Q34451441 | ||
| Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets | Q34540552 | ||
| Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer | Q34996364 | ||
| Pathogen inactivation technology: cleansing the blood supply | Q36044573 | ||
| Protecting the blood supply from emerging pathogens: the role of pathogen inactivation | Q36106339 | ||
| The 2003 West Nile virus United States epidemic: the America's Blood Centers experience | Q40511206 | ||
| West Nile virus blood transfusion-related infection despite nucleic acid testing | Q40519491 | ||
| Relative importance of immune and non-immune causes of platelet refractoriness | Q40707472 | ||
| In vitro and in vivo properties of various types of platelets | Q40846456 | ||
| Algorithm for managing the platelet refractory patient | Q41428082 | ||
| The natural history of alloimmunization to platelets | Q41905295 | ||
| Collection and transfusion of blood in the United States, 1982-1988. | Q43451949 | ||
| Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. | Q45050105 | ||
| Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light | Q45177842 | ||
| Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity | Q48623928 | ||
| Blood component use in critically ill patients | Q49123979 | ||
| A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. | Q50762273 | ||
| PLATELET QUALITY AND REDUCTION OF HLA EXPRESSION IN ACID-TREATED PLATELET CONCENTRATES | Q60313670 | ||
| Low cytokine contamination in buffy coat-derived platelet concentrates without filtration | Q71008605 | ||
| Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test | Q71770194 | ||
| Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL | Q73132195 | ||
| Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial | Q73337449 | ||
| Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness | Q73905982 | ||
| Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis | Q77302850 | ||
| Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases | Q78020820 | ||
| A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger | Q78523412 | ||
| FDA approach to evaluation of pathogen reduction technology | Q79079817 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 127-133 | |
| P577 | publication date | 2009-08-29 | |
| P1433 | published in | Transfusion and Apheresis Science | Q15758507 |
| P1476 | title | Consensus and controversies in platelet transfusion | |
| P478 | volume | 41 |
| Q53815824 | An audit of the use of platelet transfusions at Universitas Academic Hospital, Bloemfontein, South Africa. |
| Q26784256 | Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility |
| Q35750362 | Desialylation accelerates platelet clearance after refrigeration and initiates GPIbα metalloproteinase-mediated cleavage in mice. |
| Q91210166 | Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion |
| Q33428440 | Endoscopy in neutropenic and/or thrombocytopenic patients |
| Q53478275 | Evaluation of store lesion in platelet obtained by apheresis compared to platelet derived from whole blood and its impact on the in vitro functionality. |
| Q90010464 | Improvements in red blood cell transfusion utilization following implementation of a single-unit default for electronic ordering |
| Q33403555 | Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia |
| Q42662112 | Separation of in-vitro-derived megakaryocytes and platelets using spinning-membrane filtration |
Search more.